Effect of sitagliptin on depression in male wistar rats
DOI:
https://doi.org/10.18203/2319-2003.ijbcp20195787Keywords:
Depression, Inflammation, Cytokine gene expression, Oxidative stress markerAbstract
Background: Growing evidence supports relationship between depression and inflammation. The hypothesis of involvement of inflammatory pathways in depression is supported by the findings of increased levels of proinflammatory cytokines. So, we decided to evaluate the effect of sitagliptin on depression using forced swim test (FST) and possible effects of sitagliptin on serum oxidative stress markers and cytokine gene expression in rat hippocampus.
Methods: FST model was used to evaluate antidepressant effect in male wistar rats. Rats in group I (control group) were given normal saline, group II (standard group) were given fluoxetine, group III and IV (test groups) were given sitagliptin 5 mg/kg and sitagliptin 9 mg/kg respectively. All the drugs in all groups were given per orally. At the end, animals were sacrificed and blood was collected. Hippocampus of rat brain was dissected out. Serum oxidative stress markers and hippocampal pro inflammatory cytokine gene expression analysis was carried out.
Results: Sitagliptin 5 mg/kg and 9 mg/kg showed reduction in depressive symptoms and hippocampal cytokine gene expression in comparison to control. In case of serum oxidative stress markers, there was statistically significant reduction in nitric oxide levels with stagliptin 9 mg/kg. Although there was a decrease in the levels of catalase and increase in the levels of glutathione with standard and test groups, the results were not statistically significant.
Conclusions: The present study showed significant antidepressant effect activity of standard and test groups. Hence, further research should be carried out to substantiate above results.
Metrics
References
Andrade L, Caraveo A, Berglund J. The Epidemiology of Major Depressive Episodes: Results from the International Consortium of Psychiatric Epidemiology (ICPE) Surveys. Int J Methods Psychiatr. 2003;2:3-21.
Pattanayak R, Sagar R. Depressive Disorders in Indian Context- A Review and Clinical Update for Physicians. J Assoc Physians India. 2014;62:827.
Cerdá M, Sagdeo A, Galea S. Comorbid forms of psychopathology: key patterns and future research directions. Epidemiol Rev. 2008;30:155-77.
Fava M, Davidson KG. Definition and epidemiology of treatment-resistant depression. Psychiatr Clin North Am. 1996;19(2):179-200.
Zorilla P, Lubosky L, Rosenthal R, Houldin A, McKay JR. The Relationship of Depressor and Stressors to Immunological Assays. Brain Behav Immun. 2001;15:199-226.
Castagné V, Moser P, Porsolt RD. Behavioral Assessment of Antidepressant Activity in Rodents. In: Buccafusco JJ, editor. Methods of Behavior Analysis in Neuroscience. 2nd edition. Boca Raton (FL): CRC Press; 2009.
Ellman GL. Determination of sulfhydryl group. Arch. Biochem. Biophys. 1959;82:70-4.
Green LC, Wagner DA, Glogowski J, Skipper PL, Wishnok JS, Tannenbaum SR. Analysis of nitrate, nitrite and [N] nitrate in biological fluids. Anal Biochem. 1982;126:131-8.
Goth L. A simple method for determination of serum catalase activity and revision of reference range. Clin Chim Acta. 1991;196:143-51.
Peinnequin A, Mouret C, Birot O, Alonso A, Mathieu J, Clarencon D, et al. Rat pro-inflammatory cytokine related mRNA quantification by real time polymerase chain reaction using SYBR green. BMC Immunol. 2004;5(1):3.
De Muth JE. Basic statistics and pharmaceutical statiscal applications. 2nd ed. Boca Raton(FL): Chapman and Hall/CRC Press; Chapter 11. Multiple comparison tests: 2006: 229-266.
Kamble M, Gupta R, Rehan H, Gupta L. Neurobehavioral effects of liraglutide and sitagliptin in experimental models. European J Pharmacol. 2016;774:64-70.
Marques C, Mega C, Gonçalves A, Rodrigues-Santos P, Teixeira-Lemos E, Teixeira F, et al. Sitagliptin Prevents Inflammation and Apoptotic Cell Death in the Kidney of Type 2 Diabetic Animals. Mediators of Inflammation. 2014;2014:1-15.
El-Sahar A, Safar M, Zaki H, Attia A, Ain-Shoka A. Sitagliptin attenuates transient cerebral ischemia/reperfusion injury in diabetic rats: Implication of the oxidative-inflammatory-apoptotic pathway. Life Sci. 2015;126:81-6.
Tsao CW, Lin YS, Chen CC, Bai CH, Wu SR. Cytokines and serotonin transporter in patients with major depression. Prog Neuropsychopharmacol Biol Psychiatry. 2006;30:899-905.
Cattaneo A, Gennarelli M, Uher R, Breen G, Farmer A, Aitchison KJ, et al. Candidate genes expression profile associated with antidepressants response in the GENDEP study: differentiating between baseline ‘predictors’ and longitudinal ‘targets’. Neuropsycho-Pharmacol. 2013;38:377-85.
Felger J, Lotrich F. Inflammatory cytokines in depression: Neurobiological mechanisms and therapeutic implications. Neurosci. 2013;246:199-229.
Sarandol A, Sarandol E, Eker S, Erdinc S, Vatansever E, Kirli S. Major depressive disorder is accompanied with oxidative stress: short-term antidepressant treatment does not alter oxidative-antioxidative systems. Human Psychopharmacol Clin Experimental. 2007;22(2):67-73.
Gałecki P, Szemraj J, Bieńkiewicz M, Zboralski K, Gałecka E. Oxidative stress parameters after combined fluoxetine and acetylsalicylic acid therapy in depressive patients. Human Psychopharmacol Clinical and Experimental. 2009;24(4):277-86.
Galecki P, Kêdziora J, Florkowski A, Galecka E. Lipid peroxidation and Copper-Zinc Superoxide Dismutase activity in patients treated with fluoxetine during the first episode of depression (Polish). Psychiatria Polska. 2007;41:615-24.
Lukic I, Mitic M, Djordjevic J, Tatalovic N, Bozovic N, Soldatovic I, et al. Lymphocyte Levels of Redox-Sensitive Transcription Factors and Antioxidative Enzymes as Indicators of Pro-Oxidative State in Depressive Patients. Neuropsychobiol. 2014;70(1):1-9.
Downloads
Published
How to Cite
Issue
Section
